Richard Buller, VP of Pfizer, To Present at GTC’s Biomarker Europe Summit, Oct. 9-10, Berlin
07/04/2013

Richard Buller, Vice President and Head of Clinical Development of the Oncology Business Unit at Pfizer will present at GTC’s Biomarker Summit Europe 2013 on October 9-10, 2013 in Berlin, Germany.

Online PR News – 04-July-2013 – Berlin, Germany – Richard Buller, Vice President and Head of Clinical Development of the Oncology Business Unit at Pfizer, will give a presentation titled on “Drugs, Biomarkers and Diagnostics” at GTC’s Biomarker Summit Europe 2013 on October 9–10, 2013 in Berlin, Germany.

Dr. Buller’s talk will highlight the following points:

• Understanding how local laboratory tests may impact drug development and patient selection
• Understanding why the drug target can fool you
• Why you may have to define a new disease to develop your drug
• Why 98% test specificity may not be good enough
• Why one drug one diagnostic test just can’t work anymore

Richard Buller, M.D, Ph.D. was recently appointed as Head of Oncology Clinical Development at Pfizer following three years as Vice President of Translational Oncology. His former group was responsible for development of biomarker and companion diagnostic clinical strategies as well as proof of mechanism/pharmacology for drug candidates. Recent success is reflected by the approval of critoztinib for the treatment of ALK positive NSCLC. Dr Buller has authored more than 140 publications and has received numerous awards and honors including multiple year listings in the Guide to America’s Top Physicians prepared by Consumer Research Council of America. His major laboratory research interest over the years has been the molecular genetics of ovarian cancer.

GTC’s Biomarker Europe 2013 will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, novel technologies including next-generation sequencing, regulatory and reimbursement issues and companion diagnostics.

For more information, please visit www.gtcbio.com/biomarkerseuro